Plain-English translation of NCT07124910 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing corneal crosslinking, a treatment that uses vitamin B2 eye drops followed by ultraviolet (UVA) light exposure to strengthen a weakening cornea. The study compares two different treatment times — 18 minutes versus 24 minutes of light exposure — to see which works better at slowing or stopping progressive corneal diseases like keratoconus (a condition where the cornea gradually thins and becomes cone-shaped, blurring vision).
Many people with progressive corneal thinning experience worsening vision and may eventually need a cornea transplant. This treatment aims to stop that progression by making the cornea stronger, but doctors don't yet know if a shorter treatment time (18 minutes) works as well as a longer one (24 minutes).
You likely qualify if…
You likely don't qualify if…
You will visit the clinic up to 7 times over 6 months for eye exams and vision tests. During your treatment visit, vitamin B2 drops will be placed on your eye, and then your eye will be exposed to ultraviolet light — either for 18 or 24 minutes (you'll be randomly assigned to one group). The light exposure will happen in short bursts (15 seconds on, 15 seconds off) to keep your eye comfortable. After treatment, you'll have follow-up visits to check how well the treatment is working and monitor your eye health.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
United States